Table 2.

Timings of measurements of efficacy parameters

HbA1c	At screening, randomization, after 4, 12, 28, 40, 52, 65, 78, 91, 104, 117, 130, 143, 156, 169, 182, 195 and 208 weeks of treatment
Body weight	At screening, randomization, after 12, 28, 52, 78, 104, 130, 156, 182 and 208 weeks of treatment, and follow-up (4 weeks after treatment discontinuation)
Blood pressure	At screening, start of placebo run-in, randomization, after 4, 8, 12, 16, 28, 40, 52, 65, 78, 91, 104, 117, 130, 143, 156, 169, 182, 195 and 208 weeks of treatment, and follow-up (4 weeks after treatment discontinuation)

Legend: HbA_1c glycosylated hemoglobin.